

ANTIPLATELET AGENTS

KEY POINTS

- Aspirin treatment is effective in preventing recurrence of cardiovascular events in those patients with previous cardiovascular events. The absolute risk reduction in for secondary prevention is 2-4% per year with a number needed to treat (NNT) of 25-50. This risk reduction may be lower in people whose event was greater than 5 years previously.
- The absolute benefits of antiplatelet prophylaxis in primary prevention are approximately one order of magnitude lower than for secondary prevention.
- The risk of gastrointestinal and other extracranial bleeding increases with age of the patient and is increased by other patient factors (eg. previous GI bleeding/ulceration history, concurrent medications, smoking and alcohol use).
- The risk of major bleeding with dual antiplatelet agents is more than twice that of either agent alone.
- Recurrent minor bleeding can have a significant impact on patients' quality of life.
- Antiplatelet medications include:
 - Thienopyridines: clopidogrel, prasugrel (used in combination with aspirin for unstable angina)
 - Aspirin (< 150 mg)
 - Dipyridamole
 - Ticagrelor (used in combination with aspirin for unstable angina)

CONTEXT

This guide considers the use of antiplatelet agents in the prevention of primary and secondary cardiovascular events.

RECOMMENDED DEPRESCRIBING STRATEGY

- | | |
|---|---|
| 1 | Patients with a high risk of gastrointestinal bleeding (eg elderly, taking other GI bleed inducing agents such as NSAIDs, SSRIs and corticosteroids, alcohol users, smokers) should be considered for cessation of antiplatelet agents. |
| 2 | Patients with a low cardiovascular risk should be considered for cessation of antiplatelet agents. |
| 3 | Patients receiving dual antiplatelet agents should have one of these ceased 12 months (at the latest) after the acute event. For patients where bleeding risk is higher, earlier cessation may be appropriate. |
| 4 | Patients with adverse effects associated with antiplatelet agents should be reassessed for the ongoing risk vs benefit of the antiplatelet agent. |
| 5 | Patients with a limited prognosis should be considered for cessation of antiplatelet agents. |
| 6 | Antiplatelet agents can usually be ceased without the need for tapering. |

EFFICACY

PRIMARY PREVENTION

For primary prevention, the balance between vascular events avoided and major bleeds caused by aspirin is substantially uncertain. The risks without aspirin, and hence the absolute benefits of antiplatelet prophylaxis, are approximately an order of magnitude lower than in secondary prevention (4 vs 38 per 1000 patients benefit).

There are nine available trials examining the use of aspirin for primary prevention - British Doctors' Trial (BDT), Physicians' Health Study (PHS), Thrombosis Prevention Trial (TPT), Hypertension and Optimal Treatment (HOT), Primary Prevention Project (PPP), Women's Health Study (WHS), Prevention of Progression of Arterial Disease and Diabetes (POPADAD), Japanese primary prevention of Atherosclerosis with Aspirin for Diabetes (JPAD), Aspirin for Asymptomatic Atherosclerosis (AAA).

The key significant results are summarised below:

- PHS⁶ : 34% reduction in MI (ARR 0.185% pa, NNT=540)
- TPT⁷ : 20% reduction in MI (ARR 0.23% pa, NNT= 435)
- HOT⁸ : 15% reduction in any cardiovascular event (ARR 0.16% pa, NNT= 625); 36% reduction in MI (ARR 0.13% pa, NNT=769)
- PPP⁹ : 23% reduction in any cardiovascular event (ARR 1.9% over 4 years, NNT 53) and 44% reduction in cardiovascular mortality (ARR 0.6% over 4 years, NNT= 167)
- WHS¹⁰ : 17% reduction in stroke (ARR 0.255%, NNT=392)




Figure 1: Absolute benefit of aspirin for patients with different annual cardiovascular risk.




Figure 2: Estimated rates of gastrointestinal complications in men, according to age and presence or absence of GI complications.¹⁷




Figure 3: Predicted 5 year effects of aspirin for patients with different levels of CHD risk.¹⁷

< EFFICACY continued from page 1

■ BDT¹¹, POPADAD¹², AAA¹³, JPAD¹⁴: No significant findings

Trial results were mixed to some degree, but the preponderance of evidence suggested that aspirin decreases CVD risk, including MI and stroke by 6-30%.

A number of meta-analyses of these trials have been undertaken.^{4,15,16} Overall, aspirin allocation yielded a 12% proportional reduction in major vascular events, due mainly to a reduction by about one-fifth in non-fatal myocardial infarction. This proportional benefit would translate into a number-needed-to-treat (NNT) of ~2000 low-risk individuals to prevent one non-fatal myocardial infarction.

Absolute benefit of aspirin therapy can therefore be related directly to absolute risk of a cardiovascular complication. In Figure 1 (left), the number needed to treat to prevent a vascular event increases from 20 in patients with stable angina to 1667 in healthy subjects.¹⁷

SECONDARY PREVENTION

Low-dose aspirin has been shown to be effective in preventing about one-fifth of atherothrombotic vascular complications (non-fatal myocardial infarction, non-fatal stroke, or vascular death) in patients with previous myocardial infarction, stroke, or transient cerebral ischaemia.^{1,2,3,4}

This corresponds to an absolute reduction of about 10-20 per 1000 patients in the yearly incidence of non-fatal events, and to a smaller, but still definite, reduction in vascular death.

In 1994, the Antiplatelet Trialists' Collaboration,⁵ concluded that owing to the higher baseline risk, the absolute benefit is greater in older than in younger patients. In patients below 65 years of age, 11% of patients taking aspirin had vascular events compared to the baseline risk of 14.3% for patients taking placebo (ARR 3.3%, NNT= 30). For patients over 65 years of age, the baseline event rate was 23.2% and this was compared to the aspirin event rate of 18.7% (ARR 4.5%, NNT= 22).

In 2002, the Antithrombotic Trialists' Collaboration analysed 16 trials of long-term aspirin use with doses ranging from 50 - 150 mg/day for secondary prevention of CVD events, including over 17,000 subjects and 3,306 serious vascular events.⁴ In these trials, aspirin use resulted in significant reductions in serious vascular events including stroke and coronary events in both men and women and low dose regimens (75 - 100mg/day) were found to be as effective as higher doses.

Aspirin use as a secondary prevention measure for serious CVD events is well-accepted and recommended by several major organizations.

DUAL ANTIPLATELET THERAPY

Dual antiplatelet therapy is now recommended by the American Heart Association (AHA) guidelines for use after acute cardiac syndromes (unstable angina, myocardial infarction, coronary artery procedures) for 12 months, unless there are significant contraindications, in which case aspirin alone is recommended.¹⁸

Patients age 75 and older have been underrepresented in clinical trials of acute coronary syndrome and specific guidance for duration of dual antiplatelet therapy is unclear. Indeed, the AHA guidelines state "Management decisions for older patients with NSTEMI-ACS should be patient centred, and consider patient preferences/goals, comorbidities, functional and cognitive status, and life expectancy."^{4B}



ADVERSE EFFECTS

The balance between preventing vascular occlusion and causing excess bleeding with aspirin depends critically on the absolute thrombotic (see Figure 2) vs haemorrhagic risk of the patient (see Figure 3). In elderly patients with a history of a gastrointestinal ulcer, taking aspirin, the NNH (number needed to harm) is estimated as 17, while in younger patients with no prior GI history, the NNH is 1667.

While patients at relatively low cardiovascular risk may not have a net clinical benefit, in patients at high risk of cardiovascular or cerebrovascular complications (eg. patients with unstable angina or prior myocardial infarction), the absolute benefit of aspirin prophylaxis will likely outweigh the published rate of harm of a 1-2/1000 rate of GI bleeding per year.

The published rate is, however, based on clinical trial participants, and older patients and those with prior gastrointestinal issues are often excluded from such studies. Other important risk factors for extracranial (predominantly gastrointestinal) bleeds are diabetes, male gender, alcohol use, smoking, high blood pressure, concurrent medications (especially steroids, NSAIDs, SSRIs or anticoagulants). As an example, the risk of upper GI bleeding with aspirin was examined in a meta-analysis of both randomised controlled trials and observational studies.¹⁹ The odds ratio for upper GI bleeding in randomised controlled trials was 1.5 (95% CI 1.2-1.8) whereas the ratio in observational studies was 3.1 (95% CI 2.5-3.7).¹⁹ In addition, the rate of gastrointestinal mucosal injury in 281 of 3162 patients over 65 years of age who were low dose aspirin users was 36% compared to 27.5% in the non-users.²⁰

The benefits and the extracranial bleeding risks are summarised in Figure 3 on page 2. For patients at high cardiovascular risk (>10% per 5 years) the NNH was 1000 vs the NNT of 500. That is for every 100 high risk patients treated for 5 years there is estimated to be 2 vascular events avoided and 1 major extracranial bleed.¹⁷

DUAL ANTIPLATELET THERAPY

It is clear that dual antiplatelet therapy (particularly clopidogrel plus aspirin) is associated with a higher risk of bleeding than a single antiplatelet agent. In 2009, authors studying stroke risk evaluated the bleeding risk of a range of antithrombotic agents and combinations.²¹ Total bleeding occurred at mean rates of:

- 4.8% with aspirin (< or =325mg/day) alone,
- 2.9% with clopidogrel alone,
- 3.6% with aspirin plus dipyridamole and
- 10.1% with aspirin plus clopidogrel.

Major bleeding occurred at mean rates of 1% with aspirin (< or =325mg/day) alone, 0.85% with clopidogrel, 0.93% with aspirin plus dipyridamole and 1.7% with aspirin plus clopidogrel.²¹



FACTORS TO CONSIDER BEFORE DEPRESCRIBING

IN FAVOUR OF DEPRESCRIBING

LOW CARDIOVASCULAR EVENT RISK

- ✓ The main factor to consider is the ongoing cardiovascular risk in the patient. As all available cardiovascular risk calculators do not cater for patients older than 75 years, an individual assessment needs to be conducted. To determine the benefits of continuing antiplatelet therapy, the assessment should consider:

- co-existing risk factors
- patient's prognosis
- potential impact of a cardiovascular event.

PRESENCE OF SUSPECTED ADVERSE EFFECT

- ✓ Significant signs of excess effect of aspirin that impact on quality of life (eg. recurrent minor bleeding interfering with daily activities). Covert gastrointestinal bleeding can contribute to the development of anaemia. The presence of anaemia in a patient is reason for a review of the ongoing risks vs benefits of antiplatelet therapy.

AGAINST DEPRESCRIBING

- ✗ Patients who are well and functionally independent with five or more years life expectancy.



DISCONTINUATION SYNDROMES

There are some reports of and some theoretical support for the contention that ceasing antiplatelet agents is associated with a short term increase in risk of thrombotic events.

In patients prescribed with low-dose aspirin for the secondary prevention of cardiovascular or cerebrovascular events, discontinuation of antiplatelet therapy (for non-compliance, adverse effects, change of therapy or surgery) was associated with a 40% increase in the relative risk of ischaemic stroke,²² and myocardial infarction²³ compared with continuation of therapy.

Aspirin suppresses thromboxane (TXA₂) thereby suppressing platelet aggregation, while simultaneously suppressing production of PGI₂ which may result in a prothrombotic effect. There is some support for the notion that cessation of aspirin allows an unopposed prothrombotic state to develop for a few days after cessation. This has been tested in an animal model,²⁴ and is supported by some reports of ischaemic stroke, cardiovascular problems and lower limb ischaemia 7-10 days after cessation of aspirin.^{25, 26, 27}

Most antiplatelet agents permanently disable platelet function for the duration of the life of that particular platelet. The life of a circulating platelet is 10 days.

RESOURCES

- ☒ QUICK REFERENCE GUIDE
- ☒ ANTIHYPERTENSIVES GUIDE
- ☒ ANTIPLATELET AGENTS GUIDE
- ☒ ANTIPSYCHOTICS GUIDE
- ☒ BENZODIAZEPINES GUIDE
- ☒ BISPHOSPHONATES GUIDE
- ☒ STATINS GUIDE
- ☒ VITAMIN D & CALCIUM GUIDE



www.consultantpharmacyservices.com.au



www.primaryhealthtas.com.au

REFERENCES

- Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet* 2009;373:1849-1860.
- Sreenivasa Rao Kondapally Seshasai, et al. Effect of Aspirin on Vascular and Nonvascular Outcomes Meta-analysis of Randomized Controlled Trials *Arch Intern Med*. 2012;172(3):209-216.
- Ghazaleh Gouya et al. Antiplatelet Treatment for Prevention of Cerebrovascular Events in Patients With Vascular Diseases A Systematic Review and Meta-Analysis. *Stroke*. 2014;45:492-503.
- Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002;324:71-86.
- Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ* 1994 308 81-106.
- Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. *N Engl J Med* 1989;32:129-135.
- The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. *Lancet* 1998;351:233-241.
- Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *HOT Study Group. Lancet* 1998;351:1755-1762.
- de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. *Lancet* 2001;357:89-95.
- Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med* 2005;352:1293-1304.
- Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, Gilliland J, Doll R. Randomised trial of prophylactic daily aspirin in British male doctors. *Br Med J (Clin Res Ed)* 1988;296:313-316.
- Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. *BMJ* 2008;337:a1840.
- Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. *JAMA* 2010;303:841-848.
- Ogawa H, Makayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. *JAMA* 2008;300:2134-2141.
- Raju N, Sobieraj-Teague M, Hirsh J, O'Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. *Am J Med* 2011;124: 621-629.
- Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. *Am J Cardiol* 2011;107: 1796-1801.
- Patrono C. Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? *European Heart Journal* (2013) 34, 3403-3411.
- 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes *JACC VOL. 64, NO. 24, 2014*.
- Vera E, Valkhoff et al. Low-dose acetylsalicylic acid use and the risk of upper gastrointestinal bleeding: A meta-analysis of randomized clinical trials and observational studies. *Can J Gastroenterol* 2013;27(3):159-167.
- Shimada Y et al. Upper Gastrointestinal Mucosal Injury and Symptoms in Elderly Low-Dose Aspirin Users. *Gastroenterology Research and Practice Volume 2015, Article ID 252963, 7 pages*.
- Usman MH. Et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? *Am J Cardiol*. 2009 Apr 15;103(8):1107-12.
- Garcia Rodriguez LA, Cea-Soriano L, Hill C, Johansson S. Increased risk of stroke after discontinuation of acetylsalicylic acid. A UK primary care study. *Neurology* 2011;76:740-746.
- Garcia Rodriguez LA, Cea-Soriano L, Marti'n-Merino E, Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. *Br Med J* 2011;343:d4094.
- Christian Dautrempuich et al. Aspirin Discontinuation Syndromes: Clinical Implications of Basic Research Studies. *Am J Cardiovasc Drugs* (2013) 13:377-384.
- Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. *Neurology*. 2004;62(7):1187-9.
- Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. *Arch Neurol*. 2005;62(8):1217-20.
- Armstrong MJ, Schneck MJ, Biller J. Discontinuation of perioperative antiplatelet and anticoagulant therapy in stroke patients. *Neurol Clin*. 2006;24(4):607-30.